

Disclaimer

In WHO guidelines, the primary interest is to serve WHO's Member States by producing recommendations that improve the health and well-being of populations, globally or in specific areas or countries. Accordingly, WHO normative guidance needs to be developed according to a process that avoids or effectively manage conflicts of interest. Secondary interests are all interests other than the primary one that could be affected or potentially affected by a recommendation or guideline. All individuals and organizations involved in developing a guideline have secondary interests, which in most cases are legitimate and appropriate in their own right. Such interests include, for example, a technical expert's desire to publish or obtain funding for his or her research, or a stakeholder's desire to advocate for a disease or condition. Problems arise, however, when the primary and secondary interests of the parties involved in guideline development are in conflict and, as a result, an individual's secondary interests put them at risk of making decisions that are detrimental to the primary interest. In other words, a conflict of interest exists when the primary and secondary interests are not aligned and there is a chance that, because of this, the person will make decisions that undermine or subvert the primary interest.

In order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with WHO meetings and activities involving the provision of technical/normative advice, the names and brief biographies of individuals ("Published Information") being considered for participation in a WHO-convened Guideline Development Group are disclosed for public notice and comment.

The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.

The comments received by WHO through the public notice and comment process are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Comments brought to the attention of WHO through this process are an integral component of WHO's conflict of interest assessment process and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert and disclose to this expert the name and affiliation of the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.

Guideline Development Groups provide technical and/or normative advice and recommendations to WHO. Participation in a Guideline Development Group convened by WHO does not necessarily mean that the views expressed by the expert concerned are shared by WHO and/or represent the decisions or stated policy of WHO.

The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interests, is reported publically herein in accordance with WHO policies.

List of individuals being considered for participation in the Guideline Development Group

Listed in the alphabetical order of last name

- | | |
|--|--|
| 1. First name and Surname | Lisa Bero |
| Institutional affiliation | The University of Sydney
The Cochrane Collaboration |
| Academic degrees | BSc PhD |
| City and country of primary residence | Sydney, Australia |

Biography

Lisa Bero is Professor and Chair of the Medicines Use and Health Outcomes at the School of Pharmacy and Charles Perkins Centre, University of Sydney. She is a researcher in evidence-based health care who is internationally renowned for her studies on the integrity of clinical and basic research evidence that is used to influence health policy. She directs the multidisciplinary Evidence, Policy and Influence Collaborative at the Charles Perkins Centre. This group consists of 3 research “nodes”: 1) Bias, 2) Evidence Synthesis and 3) Pharmaceutical Policy. The work explores what constitutes evidence and how to reduce bias in the evidence base. Specific areas of interest are in the design, conduct and reporting of research and how to communicate research findings in a clear and convincing way to a variety of stakeholders. She is also Senior Editor, Cochrane Public Health and Health Systems Network. Professor Bero has served on national and international committees related to conflicts of interest, evidence and decisions.

- | | |
|--|--|
| 2. First name and Surname | Yingyao Chen |
| Institutional affiliation | Fudan University |
| Academic degrees | BMed MSc PhD |
| City and country of primary residence | Shanghai, The People’s Republic of China |

Biography

Yingyao Chen is Professor of Health Services at the School of Public Health, Fudan University, Director of the Key Lab of Health Technology Assessment (National Health Commission) at Fudan University, and Director of WHO Collaborating Center for Health Technology Assessment and Management at Fudan University. As well, he is the Associate Dean of the School of Public Health, responsible for international collaborations. His academic interests focus on health technology assessment, health policy, health economics, and hospital management. He serves as vice chairman of the Public Health Economics Committee affiliated to China Health Economic Association, and vice chairman of Birth Defects Prevention Committee affiliated to China Healthy Birth Science Association.

- 3. First name and Surname** Amadou Moctar Dièye
Institutional affiliation Ministère de la Santé et de l'Action sociale, Senegal
Université Cheikh Anta Diop de Dakar, Senegal
Academic degrees Diplôme d'Etat de Docteur en Pharmacie, Diplôme d'Etudes Approfondies de Pharmacologie, Doctorat ès Sciences
City and country of primary residence Dakar Senegal

Biography

Amadou Moctar Dièye was the Chief Pharmacist of the Ministère de la Santé et de l'Action sociale in Senegal , from September 2013 to June 2019, and is now the Director of Laboratories of the same Ministry and a Professor of Pharmacology at the Université Cheikh Anta Diop de Dakar. His areas of expertise include the promotion of the use of generic medicines, clinical trials, pharmacovigilance, analysis of Marketing Authorization Application dossiers for human and veterinary medicines, and anti-doping policies.

- 4. First name and Surname** Andrew Hill
Institutional affiliation The University of Liverpool
Academic degrees PhD
City and country of primary residence Liverpool, The United Kingdom

Biography

Andrew Hill graduated from Oxford University, and then worked on HIV at St Mary's Hospital in London. He has a PhD from the University of Amsterdam. He is a Senior Visiting Research Fellow at Liverpool University in the UK, specializing in treatment access issues. His research team works on the costs of production of drugs to treat HIV, viral hepatitis, TB and cancer. He also works as an advisor to the World Health Organization, UNITAID and the Clinton Foundation.

- 5. First name and Surname** Tanya Potashnik
Institutional affiliation Patented Medicine Prices Review Board, Government of Canada
Academic degrees BA (Economics and Business) MA (Economics)
City and country of primary residence Ottawa, Canada

Biography

Tanya Potashnik is the Director of Policy and Economic Analysis for a pricing regulatory authority in Canada, the Patented Medicines Prices Review Board. She has over 25 years of experience in the area of pharmaceutical pricing, regulation, reimbursement, formulary management and market dynamics in Canada, the US and Europe. A career public servant, Tanya has dedicated her professional life to improving access and affordability for patients in Canada and driving change through evidence based decision-making. Tanya played a key role in the early adoption of HTA in Canada and in leading the recent regulatory changes aimed at lowering drug costs and supporting the sustainability of Canada's publicly funded health care system.

- 6. First name and Surname** Shadi Saleh
Institutional affiliation American University of Beirut, Lebanon
Academic degrees BS MPubHlth PhD
City and country of primary residence Beirut, Lebanon

Biography

Shadi Saleh is the Founding Director of Global Health Institute and Professor of Health System and Financing at the American University of Beirut, where he is also Associate Vice President for Health Affairs. His areas of expertise are in evidence-based decision-making, economic evaluation and modeling, and healthcare financing policy. He has a

track record of providing innovative solutions in the pharmaceutical industry. He serves as Associate Editor for Health Services Research for BMC Research Notes and an editorial board member of Health Systems and Reform journal. He is an elected board member of the Consortium of Universities in Global Health. He is a Commissioner in the Lancet Commission on Syria where he co-leads the Health Systems and Rebuilding Thematic Group. He served as an appointed member of the National Emergency Social Protection Project and the Committee on Universal Health Coverage with the Ministry of Public Health in Lebanon. He also serves as a World Bank, WHO and UN advisor for health care financing policy and system strengthening projects.

1. **First name and Surname** Vania Cristina Canuto Santos
Institutional affiliation Ministério da Saúde, Brasil
Academic degrees MSc
City and country of primary residence Brasília, Brazil

Biography

Vania Cristina Canuto Santos is a health economist and currently a Director at the Brazilian Public Health System's National Commission for Health Technologies Incorporation (CONITEC), where she has worked at since 2011. From 2002 to 2009, she worked on price regulation of medicines in the Pharmaceutical Market Regulation Chamber (CMED) in Brazil.

2. **First name and Surname** Sakthivel Selvaraj
Institutional affiliation Public Health Foundation of India
Academic degrees PhD
City and country of primary residence New Dehli, India

Biography

Sakthivel Selvaraj currently holds the position of Director and Professor, Health Economics, Financing and Policy, at the Public Health Foundation of India (PHFI), New Delhi. He is currently engaged in research, teaching and advocacy in the area of health systems, and in specific, health care financing and access to medicines. He contributed significantly to the development of HLEG (High Level Expert Group) report on UHC. Similarly, he contributed immensely to the development of State Health Policy of Uttar Pradesh. Earlier, he was engaged as a Health Economist in the National Commission on Macroeconomics and Health, Ministry of Health and Family Welfare, New Delhi during 2004-05. His recent work underpinning access to medicines include financing of pharmaceuticals, procurement and supply chain of medicines, price regulation, pharmaceutical patents and economics of rational use of medicines.

3. **First name and Surname** Netnapis Suchonwanich
Institutional affiliation HiTAP, Ministry of Public Health, Thailand
Academic degrees BPharm M.IT Management
City and country of primary residence Muang Nonthaburi, Thailand

Biography

Netnapis Suchonwanich is Advisor to Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand. She was formerly Deputy Secretary-General of National Health Security Office in Thailand. She played a key role in Universal Coverage Scheme development since the beginning of UHC implementation in 2002. She has developed many health insurance information systems which cover the core business applications such as Beneficiaries enrollment system, Birth registry and neonatal defect, provider registration, financial and accounting system, electronic claim system with automatic financial tracking process. She has been nominated as

Member of National Essential Drug Subcommittee, Member of Health Economic working group and Chair of Price Negotiation working group for competitive medicines submitted to be essential medicines in Thailand.

4. **First name and Surname** Fatima Suleman
Institutional affiliation National Pricing Committee for Medicines, South Africa
University of KwaZulu-Natal, South Africa
Academic degrees BPharm MPharm PhD
City and country of primary residence Durban South Africa

Biography

Fatima Suleman is a Professor, and Director of the World Health Organization for Pharmaceutical Policy and Evidence Based Practice in the Discipline of Pharmaceutical Sciences at the University of KwaZulu-Natal, South Africa. She is Chair of the Pricing Committee for Medicines for South Africa's National Ministry of Health, and was a member of the expert panel for the 2015 *WHO guideline on country pharmaceutical pricing policies*. From September 2016 to September 2018, she was a Professor and the Prince Claus Chair of Development and Equity for the theme Affordable (Bio)Therapeutics for Public Health at the Faculty of Sciences, Utrecht University, The Netherlands. Her research focus is on pharmaceutical policy, and systems. She has previously served on the Essential Medicines Technical Committees in South Africa and as an advisor to several WHO panels.

5. **First name and Surname** Sabine Vogler
Institutional affiliation Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute)
Academic degrees Mag. rer. soc. oec., PhD
City and country of primary residence Vienna, Austria

Biography

Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is Head of the Pharmacoeconomics Department of Austrian Public Health Institute. She is a senior health economist with in-depth knowledge on countries in the WHO European region and beyond with regard to pharmaceutical pricing / prices, reimbursement and distribution, as well as cost-containment reforms, access and affordability issues. Sabine Vogler coordinated several research projects at national and European levels, including the PPRI (Pharmaceutical Pricing and Reimbursement Information) and the PHIS (Pharmaceutical Health Information System) projects. She is a member of the Editorial Boards of *Pharmacoeconomics* and *Generics and Biosimilars Initiative Journal*. She is also on the International Advisory Board of the *Pharmaceutical Policy and Practice (JOPPP) Journal*, as well as the Associate Editor for JOPPP journal, *Cost Effectiveness and Research Allocation* and of *BMC Health System Research*. Furthermore, she is a board member of the European Drug Utilisation Research Group (EuroDURG) and of the Austrian Health Economics Association (ATHEA). In 2017, she was Visiting Fellow at the Department of Economics at the University of Bologna in Italy. In 2019, she was presented, together with Margaret Ewen of Health Action International, with the Helen-Clark-JOPPP Award for Pharmaceutical Policy and Practice Research.

6. **First name and Surname** Jo Watson
Institutional affiliation Pharmaceutical Benefits Advisory Committee, Australia
Academic degrees B.Soc.Sci
City and country of primary residence Sydney, Australia

Biography

Jo Watson is the Deputy Chair of the Australian Government Pharmaceutical Benefits Advisory Committee. She is also the Chair of the Health Technology Assessment Consumer Consultative Committee, Deputy Chair of the Consumers Health Forum Australia, and a long standing consumer nominee and community advocate.

7. First name and Surname Rasha Ziada
Institutional affiliation Chairperson of central administration for pharmaceutical affairs CAPA ,
Ministry of Health.
Academic degrees BPharm, Dipl. Clin. Pharm, MHIthEcon
City and country of primary residence Cairo, Egypt

Biography

Rasha Ziada is Chairperson of the Central Administration of Pharmaceutical Affairs (CAPA) at the Egyptian Government Ministry of Health and Population, which is the main part of the National Regulatory Agency of Egypt. She is also the heads of three technical committees at the Ministry of Health: Pricing Committee, Technical Committee for drug registration, and Committee for Pharmacoeconomics. She was the Department Head of pharmaceutical policy and planning in CAPA with in-depth knowledge on pricing, health and pharmaceutical policy, and pharmaceutical regulation in Egypt, Arab countries, and across the Middle East with regard to pharmacoeconomics, health economics, reimbursement as well as all issues relating to pharmaceutical regulations. Rasha Ziada is responsible for the coordination of several pharmaceutical regulatory reform projects at the national level in Egypt and regional level in Africa.